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Summary 
Numerous vires-specific, class I-restricted cytotoxic T  lymphocyte (CTL) epitopes have been 
identified,  yet little information is available regarding the specificity of the  CTL response in 
persons of the same human histocompatibility leukocyte antigen (HLA) type. In this study, the 
human immunodeficiency virus (HIV) 1 envelope-specific CTL response was evaluated in five 
HLA-B14-positive persons. CTL responses specific for a previously described nine--amino acid 
epitope  in  gp41  (aa  584-592,  ERYLKDQQL)  could be identified  in  all  subjects,  and  CTL 
clones specific for this epitope could be isolated from four persons. Despite heterogeneous T 
cell receptor usage, the fine specificity of the clones was similar, as defined by recognition of 
alanine-substituted peptides as well as peptides representing natural HIV-1 sequence variants. 
Correlation with in vivo virus sequences revealed that the dominant species in two of the sub- 
jects  represented  poorly  recognized  variants,  with  a  K--)Q  substitution  at  amino  acid  588, 
whereas no variants were observed in the other two subjects. Although clonal type-specific re- 
sponses to these dominant variants could be identified,  the  magnitude  of these responses re- 
mained small, and the dominant CTL response was directed at the minor in vivo variant. These 
studies  indicate  that  despite  similar epitope-specific immunologic pressure  in  persons of the 
same HLA type, the in vivo quasispecies may differ, and that the major in vivo immune re- 
sponse to a given CTL epitope can be directed at a minor variant. 
H  IV-1 infection elicits a profound HLA class I-restricted, 
.vires-specific CTL response in some persons, and this 
CTL response appears to correlate with maintenance of the 
asymptomatic state (1-3). These CD8 + CTL recognize en- 
dogenously  processed viral antigen  on  the  surface  of in- 
fected cells through a specific interaction of the TCR with 
the HLA-antigen complex on the target cell surface. The 
TCR is a heterodimer consisting of ot and [3 chains that are 
formed by the rearrangement of noncontiguous V, D, andJ 
regions. The addition of nongermline-encoded nucleotides 
at the junctions  of these rearranged segments increases re- 
ceptor diversity,  and allows for an enormous repertoire  of 
distinct  TCR  able to recognize a wide  range  of peptide- 
HLA combinations. 
Studies of the TCR usage by class 1-restricted CTL spe- 
cific for viral epitopes have attempted to  assess the  struc- 
ture--function relationship  of the  TCR  and to  define  the 
extent of TCR diversity in the host-response to infection. 
Previous studies in  humans  have concentrated  on the  re- 
sponse  to  an  acute  infection,  influenza  A,  and  have  de- 
scribed  limited  TCR  usage  against  an  HLA-A2  matrix 
epitope (amino acids [aa]  ~ 57-68)  (4,  5) and an HLA-B27- 
restricted  nucleoprotein  epitope  (aa  383-391)  (6).  These 
studies suggest there may be constraints on TCR usage for 
recognition of defined epitopes. Limited studies have ana- 
1Abbreviations used in this paper: aa, amino acid; B-LCL, EBV-transformed 
B-lymphoblastoid  cell line. 
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(7-9).  The  ability of distinct CTL  clones specific for  the 
same epitope to recognize sequence variation within the cog- 
hate epitope has not been defined, nor have these fine speci- 
ficities been related to variants that arise in vivo. 
We have previously demonstrated that a dominant HIV-1- 
specific CTL response to a B14-restricted epitope in gp41 
(ERYLKDQQL,  aa  584-592)  could be  due  to  an  oligo- 
clonal expansion of CTL that can persist for at least 5 yr (7, 
and our unpublished data). To characterize the response to 
this epitope in persons with diverse clinical courses of dis- 
ease, five HLA-B14-positive subjects were analyzed for the 
ability to  recognize this epitope.  CTL  clones were  estab- 
fished from  four  of these  subjects.  The  fine  specificity of 
these CTL clones was determined by evaluating lysis of tar- 
get cells incubated with peptides containing alanine substi- 
tutions,  as  well  as  peptides  representing  known  HIV-1 
variants.  Despite  a  relatively heterogeneous  TCR  usage, 
our results indicate a striking similarity in the ability of dif- 
ferent  CTL  clones to  recognize  sequence  variants.  How- 
ever,  the  dominant  detectable  quasispecies in  vivo  varies 
markedly among subjects, and in some persons the domi- 
nant quasispecies is targeted by a minority CTL population. 
Materials and Methods 
Subjects.  Subjects 15160  and 18030  are part of the San Fran- 
cisco men's health study (10).  At the time of isolation of CTL 
clones from these subjects, 15160 was infected with HIV-1  15 yr 
and was asymptomatic with a CD4 count of 1,213/mm 3. Subject 
18030 was infected for "-'6 yr and had a CD4 count of 692. Sub- 
ject LWF is an infected laboratory worker who has been followed 
for several years and who had a CD4 count of 284. Subject 010- 
115i had been infected at least 5 yr and was asymptomatic with a 
CD4 count of 819.  Subject 010-115i previously has been shown 
to  have  significant envelope-specific CTL  activity (7,  11).  All 
subjects gave written informed consent for these studies. 
Cell Lines.  EBV-transformed B lymphoblastoid cell lines (B- 
LCL) were established and maintained in RPMI  1640  medium 
containing 20% (vol/vol) heat-inactivated FCS (both from Sigma 
Chemical Co.,  St.  Louis, MO)  and supplemented with r-gluta- 
mine  (2  raM),  penicillin (50  U/ml),  streptomycin (50  p~g/ml), 
and Hepes (10 raM) as described previously (12,  13). All B-LCL 
were  free  of mycoplasma  infection  by  standard  culture  tech- 
niques. 
HLA typing.  HLA typing was performed by the  San  Fran- 
cisco Department of Public Health for subjects 15160 and 18030, 
by Dr. Dean Mann (Immunogenetics Section, Laboratory of Vi- 
ral Carcinogenesis, National Cancer Institute, Bethesda, MD) for 
LWF, and by the Massachusetts General Hospital Tissue Typing 
Laboratory for  subject  010-115i  by  standard  serological tech- 
niques.  The  class  I  HLA types of these  subjects are  010-115i: 
A2,28;  B14,52;  Cw8;  15160:  A3,32;  B14,44;  18030:  A2,33; 
B14,27; Cwl; and LWF: A2,11; B14,35. 
HIV-1 Sequencing.  HIV-1 envelope sequences within the gp41 
epitope were determined by a nested PCR technique as described 
in (3). 
Synthetic Peptides.  The nine--amino acid peptide gp41/584-592 
and all peptides representing HIV-I variants or alanine substitu- 
tions were  synthesized as  COOH-terminal acids on  a  Synergy 
peptide  synthesizer  (model  432A  Applied  Biosystems,  Foster 
City, CA). The amino acid numbering is according to the PV22 
sequence. 
Isolation of HIV- 1 Envelope-specific CTL Clones.  CTL clones from 
subjects 15160,  18030,  and 010-115i were isolated as previously 
described (7). Briefly, PBMC  obtained by separation on Fico/l- 
sodium diatrizoate (Histopaque 1077; Sigma Chemical Co.) were 
cloned at limiting dilution with irradiated allogeneic feeder cells, 
R10 with 100 U/ml rlL-2, and PHA at 0.25  p,g/ml (Nurex Di- 
agnostics Inc., Atlanta, GA). Clones were screened for CTL ac- 
tivity against autologous targets infected with recombinant vac- 
cinia virus expressing the  HIV-1  envelope glycoprotein of the 
BH8 isolate of HIV-1  or against autologous B-LCL pulsed with 
peptide gp41/584-592.  The  CTL  clones LWF A20,  LWF C8, 
and  18030  G14 were derived by incubating PBMC with autolo- 
gous B-LCL pulsed with gp41/584-592 for 10 d. These cells were 
then  cloned at limiting dilution and screened for the ability to 
lyse Vac-Env-infected autologous B-LCL and peptide-pulsed au- 
tologous B-LCL. With the exception of clone 18030  G14, all ac- 
tive clones in this paper were subcloned at 10, 3,  1, and 0.3 cells 
per well in the presence of irradiated feeder cells and PHA. Sub- 
clones from plates that exhibited growth of <30% of seeded wells 
were expanded and subjected to TCR analysis. 
Cytotoxicity Assay.  Target cells consisted of  B-LCL infected with 
vaccinia-HIV-I expression vectors, vaccinia control, or B-LCL 
incubated  with  the  indicated concentrations  of the  designated 
peptides for 60 rain during SlCr labeling. Cytolytic activity was 
determined in  a  standard SlCr-release assay  using U-bottomed 
microtiter plates containing 104 targets per well (14). 
Limiting Dilution Assays of CTL Precursors.  Precursor frequen- 
cies ofHIV-1 epitope--specific CTL were estimated by perform- 
ing limiting dilutions on fleshly isolated PBMC  followed by in 
vitro stimulation with autologous irradiated PBMC pulsed with 
peptides. PBMC  were cultured at 250-16,000  lymphocytes per 
well in 24 replicate wells of 96-well microtiter plates. Stimulator 
cells were prepared by incubating autologous PBMC with 1 l~g/ml 
of each peptide for 1 h. These cells were then washed twice with 
RPMI  1640  and irradiated. To each well of the precursor assay 
plate was  added 5  X  104  ~/-irradiated PBMC  from  a  HIV-1- 
seronegative donor  and  2.5  ￿  10  4  autologous peptide-pulsed, 
~-irradiated PBMC.  After 10-14 d, wells were split and assayed 
for  cytotoxicity on  51Cr-labeled autologous B-LCL  incubated 
with the relevant peptides, or B-LCL without peptide. The frac- 
tion of nonresponding wells was the number of wells in which 
5~Cr release did not exceed the mean plus three standard devia- 
tions of the average spontaneous release of the 24 control wells 
(15,  16). Activated cell frequency was estimated by the maximum 
likelihood method (1, 17, 18). 
PCR Amplification  of TCR-ot and -fl Sequences.  The TCR us- 
age of CTL was determined by methods previously described (7). 
Total RNA was isolated from 5 X  106 cells with Ukraspec (Cinna/ 
Biotecx Laboratories International Inc.,  Friendswood, TX)  and 
was converted into first strand cDNA with a constant region a  or 
[3 primer, and avian myeloblastosis reverse transcriptase according 
to  the  manufacturer's specifications (Promega  Corp.,  Madison, 
WI). Anchored PCR was performed on all CTL clones except 
15160  DC4. A poly G tail was added with TdT (GIBCO BRL, 
Gaithersburg, MD). A heTninested PCR was performed with pre- 
viously described primers and reaction conditions (7). The result- 
ing  products  were  cloned  into  the  pAMP1  vector  using  the 
Cloneamp  system  (GIBCO  BKL)  and  sequenced  after alkaline 
hydrolysis (19). The TCR usage  of CTL clone 15160  DC4 was 
determined by amplifying the cDNA with a panel of TCP,  Vc~ 
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Figure 1.  CTL recognition of index peptide gp41/584-592 titrated on 
autologous B-LCL. (Empty symbols) Autologous B-LCL pulsed with an ir- 
relevant control peptide; (filled symbols) autologous B-LCL pulsed with in- 
dex peptide gp41/584-592.  (U], g) 115 M21; (A, A) LWF C8; (O, 4') 
18030 B31; and (O, O) 15160 DC4. 
and VI3 primers.  In each case, only a single variable region gene 
was present  and the PCR product was sequenced  directly as de- 
scribed (7). 
Results 
Our initial finding that subject 010-115i had a vigorous 
response  to  the  relatively conserved gp41  epitope  ERY- 
LKDQQL  (aa  584-592)  (7,  11)  prompted us  to  evaluate 
whether CTL responses of identical specificity from other 
HLA-B14-positive subjects could be detected. CTL clones 
from four HLA-B14 subjects were isolated,  tested against 
panels  of peptides  representing  natural  HIV-1  sequence 
variants as well as a  series of alanine-substituted  peptides, 
and subjected to TCR analysis.  The CTL clones in this re- 
port had equivalent recognition of the index peptide as de- 
termined by serial log dilutions  of peptide  gp41/584-592 
on  autologous B-LCL,  all  requiring  a peptide  concentra- 
tion between 100 and 10 ng/ml for target cell sensitization 
to achieve 50% maximal lysis of target cells (Fig.  1). A CTL 
line  of identical  specificity had been  isolated from a  fifth 
subject  (20)  but  could not be successfully cloned in vitro 
for these  analyses. The ability of other HLA-B14 subjects 
to recognize this  epitope has  also  been reported  (21,  and 
Lieberman, J., personal communication). 
TCR  Gene  Usage of gp41/584-592-specific  CTL  Clones. 
An  examination  of the  TCR  usage  of these  CTL clones 
was  undertaken  in  order to  assess the  repertoire  of TCR 
able  to  recognize  this  epitope.  Eight  of the  nine  CTL 
clones (lines) in this report were subcloned at limiting dilu- 
tion; CTL clone 18030 G14 did not propagate well enough 
to allow subcloning.  For each of the TCR  sequences de- 
rived by anchored PCR, at least eight TCR-(x and -[3 chains 
were sequenced. Evaluation of TCR-ot sequences revealed 
considerable heterogeneity among the eight clones (Fig.  2 
A).  Two in-frame TCI~-oL chains  were  present  in  clones 
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LWF A20 and LWF C8, a situation that is thought to oc- 
cur in up to one third of or/J3 T  cells (22). Both these CTL 
clones were  derived from PBMC  incubated with B-LCL 
pulsed  with  the  gp41/584-592  peptide.  The  TCR-~x 
chains of these CTL clones were identical at the nucleotide 
level. Both of the CTL clones from subject 010-115i  had 
identical TCR-ot chains at the nucleotide level, as has been 
previously described for all clones isolated from this subject 
(7). Although clone 18030 D6 shared Jo~ usage with 18030 
B31, the N  region sequences of these clones were distinct. 
In  addition,  a  CD8-positive  cell  line  18030  G14,  which 
was  specific  for  the  B14-restricted  epitope  but  was  not 
clonal, also contained a TCR-ot nucleotide sequence iden- 
tical to that of 18030  D6, indicating that the minority se- 
quence  (2 out of 11  molecular clones sequenced)  was re- 
sponsible for the observed lysis.  In terms of Jci usage, less 
heterogeneity was observed. Four of the  CTL clones uti- 
lized JoL 9.3  and a fifth clone utilized the related sequence 
Jcl 9.12 (Fig. 2 A). Four of the clones contained an arginine 
residue in the N  region of the TCR-cx chain that may con- 
tribute to binding one of the negatively charged residues in 
this CTL epitope. 
The TCR-[3 sequences were likewise determined for all 
of the  clones  (Fig.  2  B).  Four  clones  from two  subjects 
(010-115i  and  18030)  utilized VI34  and all of these clones 
utilizedJI31.2 sequences as well. Although two [3 sequences 
were evident in the  18030  G14 cell line, TCR  sequences 
identical  to  the  minority  sequences  present  in  the  18030 
G14  cell  line  were  exclusively  present  in  a  CTL  clone 
(18030 D6) isolated from this subject 11  mo later, indicat- 
ing that these are the sequences responsible for CTL recog- 
nition of this epitope in this cell line. The clones from two 
other subjects utilized V[31 and V~12, respectively, and one 
of these clones also used J[31.2. 
The similarity among the  CTL from subjects 010-115i 
and  18030  extends  across  the  D~  region  of the  TCR-[3 
chains with V  and K  residues in the first two positions of 
the  D[3  sequences  of three  of the  four CTL clones from 
these subjects, and a D  residue in the third D[3 position in 
three of these CTL. In contrast to the observed similarities 
in TCR usage by subjects 010-115i and 18030, TCR usage 
by clones from subjects LWF and 15160 were quite heter- 
ogeneous.  However,  despite  this  heterogeneity  in  TCR 
usage, the index peptide was recognized to the same extent 
(Fig.  1), indicating that a wide range of TCR is able to rec- 
ognize a particular peptide epitope,  and that the  observed 
differences in TCR  usage do not appear to result in large 
differences in the amount of peptide required for recogni- 
tion,  even in persons with very different clinical stages of 
infection. 
gp41/584-592-specific  CTL  Clones  from  Four  Different 
Subjects Show Differences in Recognition  of Alanine-substituted 
Peptides.  Titrations  of peptides  with  sequential  alanine 
substitutions uncovered differences in the fine specificity of 
these  CTL clones.  Peptides  were  incubated  with  autolo- 
gous B-LCL at concentrations ranging from 100  ~g/ml to 
10 pg/ml; the peptide concentration resulting in 50% max- 
imal lysis  was  graphed  (Fig.  3).  Substitutions  at  positions a 
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v~14 
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N 
Y  R  T 
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CTL alpha TCR 
Jo~  #/total # 
J~  9.3 
S  G  G  S  N  Y  K  L  T  F  G  K  G  T  L 
agt  gga  ggt  agc  aac  tat  aaa  ctg  aca  ttt  gga  aaa  gga  act  ctc  10/10 
Vel4 
F  C  A  Y  R  T 
ttc  tgt  gct  tat  cgg  acg 
Jff  9.3 
S  G  G  S  N  Y  K  L  T  F  G  K  G  T  L 
agt  gga  ggt  agc  aac  tat  aaa  ctg  aca  ttt  gga  aaa  gga  act  ctc 
V(~6 
F  C  A  M  R  N 
ttc  tgt  gca  atg  aga  aat 
J~  9.3 
S  G  G  S  N  Y  K  L  T  F  G  K  G  T  L 
agt  gga  ggt  agc  aac  tat  aaa  ctg  aca  ttt  gga  aaa  gga  act  ctc 
V~3.1 
F  C  A  T  G  H 
ttc  tgt  gct  acg  ggt  cat 
V~3.1 
F  C  A  T  G  H 
ttc  tgt  gct  acg  ggt  cat 
12/12 
V~2 2 
C  A  L 
tgt  gct  ctg 
R  V  K 
aga  gtc  aaa 
V~2 3 
L  C  A  V  F  Y 
ctc  tgt  gct  gtg  ttt  tac 
V(X2  4 
I  C  V  V  R  G 
atc  tgt  gtg  gtg  aga  ggc 
9/9 
N  N  N  D  M  R 
aat  aac  aat  gac  atg  cgc 
J~l.  7 
F  G  A  G  T  R 
ttt  gga  gca  ggg  acc  aga  8/13 
J~  17.3 
Q  F  Y  F  G  T  G  T 
cag  ttc  tat  ttt  ggg  aca  ggg  aca  5/13 
v~ 
S 
agc 
v~ 
S 
agc 
v~ 
S 
agc 
v~ 
S 
agc 
v~ 
S 
agc 
VI31 
A 
gcc 
V~12.3 
s 
agt 
N-DI3-N 
V  K  D  G  A 
gtg  aag  gac  ggg  gct 
V  E  D  W  G  G  A  S 
gtt  gaa  gat  tgg  ggc  gga  gcg  agc 
V  K  V  T  S  Y 
gtt  aag  gtc  acc  tcc  tat 
V  K  D  S  S  Y 
gtt  aag  gac  agt  tcc  tat 
V  K  D  S  S  Y 
gtt  aag  gac  agt  tcc  tat 
S  G  P  G  Q  G  E  D 
agc  ggc  ccc  gga  cag  ggt  gag  gac 
G  S  R  A  S 
ggt  agt  agg  gca  agc 
CTL beta TCR 
j[~  #/total # 
Jl~ 1.2 
G  Y  T  F  G  S  G  T  R  L  T  V  V 
ggc  tac  acc  ttc  ggt  tcg  ggg  acc  agg  tta  acc  gtt  gta  12/12 
J[~  2.1 
S  Y  N  E  Q  F  F  G  P  G  T  R  L 
tcc  tac  aat  gag  cag  ttc  ttc  ggg  cca  ggg  aca  cgg  ctc  lO/lO 
J~ 1.2 
G  Y  T  F  G  S  G  T  R  L  T  V  V 
ggc  tac  acc  ttc  ggt  tcg  ggg  acc  agg  tta  acc  gtt  gta  11/11 
J[~ 1.2 
G  Y  T  F  G  S  G  T  R  L  T  V  V 
ggc  tac  acc  ttc  ggt  tcg  ggg  acc  agg  tta  acc  gtt  gta  lull 
Jl~ 1.2 
G  Y  T  F  G  S  G  T  R  L  T  V  V 
ggc  tac  acc  ttc  ggt  tcg  ggg  acc  agg  tta  acc  gtt  gta  3/11 
JI]  1.2 
Y  G  Y  T  F  G  S  G  T  R  L  T  V 
tat  ggc  tac  acc  ttc  ggt  tcg  ggg  acc  agg  tta  acc  gtt  * 
J[~ 2.7 
E  Q  Y  F  G  P  G  T  R  L  T  V 
gag  cag  tac  ttc  ggg  ccg  ggc  acc  agg  ctc  acg  gtc  10/10 
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T  G  A  N  S  K  L  T  F  G  K  G  I  T 
act  gga  gcc  aat  agt  aag  ctg  aca  ttt  gga  aaa  gga  ata  act 
J~  9.3 
s  G  G  S  N  Y  K  L  T  F  G  K  G  T  L 
agt  gga  ggt  agc  aac  tat  aaa  ctg  aca  ttt  gga  aaa  gga  act  ctc  I~I0 
J~  9.3 
S  G  G  S  N  Y  K  L  T  F  G  K  G  T  L 
agt  gga  ggt  agc  aac  tat  aaa  ctg  aca  ttt  gga  aaa  gga  act  ctc  2/12 100 
m~InrJ~)QQT. 
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Figure 3.  Titrations ofgp41/584-592 alanine-substituted peptides.  Autologous B-LCL were incubated with decreasing concentrations of each peptide. 
CTL clones were added at E/T ratios ranging from 3:1 to 10:1. The concentration ofpeptide sufficient for 50% maximal lysis is shown along the hori- 
0  zontal axis. Maximal lysis ranged from 50 to 100~. Spontaneous release values for all assays were <25%. 
P3-P6 were poorly tolerated, shifting the amount of pep- 
tide required for half-maximal lysis by ~>2 log. The substi- 
tutions at P3 (Y586A)  and P6 (D589A) were not apprecia- 
bly  recognized by  any of the  CTL  clones.  The  lack  of 
recognition ofpeptide Y586A is consistent with recent data 
showing  P3  to  be  an  important  anchor  residue  for  the 
HLA-B14 molecule (23) and is likely to reflect diminished 
HLA binding. For a few substituted peptides, recognition 
varied markedly among the clones. For example, a P1 sub- 
stitution had effects ranging from complete abrogation of 
recognition  (LWF  C8)  to  a  l-log shift in  observed lysis 
(15160 DC4). 
Figure 2.  TCR.-oe and -]3 sequences of HLA-B14-restricted, 588K-specific  CTL clones.  (*) Sequences were derived after amplification with a panel of 
TCR V~x and V[~ primers followed by direct sequencing of PCR products as described  in (7). (A) TCR-c~ sequences  of CTL clones. Nomenclature of 
TCR.-Ix sequences is according to reference 34. (B) TCR.-]3 sequences  of CTL clones. At least eight and eight TCR-ot and -[3 transcripts were sequenced 
for each CTL  clone. These sequence data  are  available from EMBL/Genbank/DDBJ under accession  numbers Z29579, Z29580,  Z29581,  Z29582, 
Z29614, U51442, U51443, U51444, U51445, U50555, U50556, U50404, U50405, and U50073. 
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site is well demonstrated in the case of an alanine substitu- 
tion at P7 (Q590A). The concentration of this peptide that 
yields 50% maximal lysis is nearly the same as that of the in- 
dex peptide for CTL clones 115 M21  and 115 E15. How- 
ever, the other CTL clones show extremely poor recogni- 
tion of this peptide, even at a concentration of 100 p~g/rnl. 
To ensure this differential degree of lysis was in fact due to 
a difference in TCR  affinity, rather than  due  to a variant 
HLA allele present in this subject, titrations of this peptide 
were performed on the B-LCL from the other three sub- 
jects and yielded  equivalent levels of lysis  by CTL clone 
115  M21  at each  of the peptide  concentrations  (data not 
shown). This confirmed the ability of B-LCL from all these 
subjects to present this peptide for CTL-mediated lysis. 
Recognition of HIV- I  Variants by gp41/ 584-5 92-specific 
CTL.  To evaluate the  role of the  TCR  in determining 
the ability of CTL to cope with HIV-1 sequence variation, 
the gp41-specific CTL clones were tested for their ability 
to  recognize  peptide  sequences  corresponding  to  known 
HIV-1 variants representing diverse HIV-1  clades.  As can 
be seen in Fig. 4, substitutions at P5 were poorly tolerated. 
The nonconservative substitutions K588G and K588Q were 
poorly recognized by all  CTL  clones  tested.  Three  CTL 
clones  were  able  to  recognize  a  peptide  representing  the 
SF2  isolate that  contained  a  conservative K588R  substitu- 
tion.  However,  despite  the  conservative substitution,  this 
peptide was poorly recognized by CTL clones from subjects 
15160 and 18030. Not all conservative amino acid substitu- 
tions allowed for continued recognition. A conservative D--~E 
ER~I~L  (m2) 
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target cells were incubated with peptides representative ofHIV-1  clades A-E. 
TCR  Heterogeneity and Recognition  of CTL  Epitope Variants Table  1.  Analysis  of HIV- 1 Genotype within  gp41/584-592  in 
Four HLA-BI 4 Subjects 
Percent HIV-1 sequence prevalence* 
Subject  Date  ERYLKDQQL (%)  ....  Q ....  (%) 
010-115i  3/91  0  (0)  11  (100) 
8/91  4  (33)  8  (67) 
4/92  1  (10)  9  (90) 
4/93  3  (25)  9  (75) 
11/93  4  (18)  18  (82) 
15160  2/94  10  (100)  0  (0) 
18030  3/94  0  (0)  9  (100) 
11/94  0  (0)  12  (100) 
LWF  12/92  9  (100)  0  (0) 
*3 ￿  106 PBMC at the indicated time points were lysed and subjected 
to nested PCR as described (3). 
substitution  at P6  (a presumed  TCR  contact site;  23) was 
poorly recognized by all  six CTL clones.  A  clear case for 
diminished TCtk binding can be made for the consensus E 
sequence  (Con  E)  which  has  a  Q-->K  substitution  at  P8 
(Q591K).  Five  of the  six  CTL  clones  tested  had  limited 
ability  to  recognize  this  peptide.  However,  CTL  clone 
LWF C8 recognized this peptide to the same level as pep- 
tide gp41/584-592.  This clone was also able  to recognize 
the consensus E peptide when titrated on the B-LCL of the 
other four subjects,  again indicating  that  differences in the 
HLA-B14 alleles  of these  subjects  did  not account for the 
difference in CTL recognition (data not shown). 
In  Two Subjects the  Predominant HIV-1  Genotype Is  Not 
Recognized  by  the  Majority  of  Their  Isolated CTL  Clones. 
To  assess  the  relationship  between  the  fine  specificity  of 
these  CTL clones and in vivo sequence  variation,  the  re- 
gion of the  HIV-1  genome  containing this  CTL  epitope 
was  sequenced  in  each  of these  subjects.  A  limiting  dilu- 
tion,  nested  PCR  technique  was  used  to  amplify HIV-1 
gp41  sequences  from  each  of these  subjects  at  the  time 
points the CTL clones were isolated (for subject 18030, the 
first  HIV-1  sequences  were  determined  at  a  time  point 
4 mo after CTL clone 18030 B31 was isolated).  In the four 
subjects,  only two  different  sequences  were  identified.  In 
two subjects,  the dominant in vivo species was identical to 
the  HXB2 sequence  in  this  region,  and  in  the  other two 
subjects (010-115i and 18030) the dominant in vivo geno- 
type  was  the  K588Q  variant  (a  glutamine  substitution  at 
P5, corresponding to the JFL variant; Table 1). The major- 
ity of CTL clones from these subjects did not recognize this 
variant at levels <10 p.g/ml (Fig. 4).  Only one CTL clone 
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Figure 5.  CTL precursor frequency analysis of PBMC from subjects 010-115i and 18030.  Autologous PBMC from each subject were incubated with 
a combination ofpeptides 588K and p17/77-85 or K588Q and p17/77-85 (SLYNTVATL), irradiated, and used as stimulator cells in a CTL precursor as- 
say as described in Materials and Methods. ([~) B-LCL, (,) p17/77-85,  (A) 588K, and (&) K588Q.  (A) PBMC from subject 010-115i stimulated with 
588K and p17/77-85.  (/3) PBMC from subject 010-115i stimulated with K588Q and p17/77-85.  (C)  PBMC from subject 18030  stimulated with 588K 
and p17/77-85.  (D) PBMC from subject 18030  stimulated with K588Q and p17/77-85. 
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Figure 6.  Peptide titrations ofgp41/584-592 variants. CTL clones from subject 18030 are tested for their ability to recognize peptides representing 
HIV-1 variants. (A) 588K, ((9) K588R, (A) K588Q, and (0) K588Q, Q591R. 
(15160  DC4)  recognized this  variant  in  addition  to  the 
588K peptide, yet this recognition did not extend below a 
concentration of 1 ~g/ml. 
The Precursor Frequency of CTL Clones Can Be Dominated 
by  CTL  that  Recognize  a Minor In  Vivo  HIV-1  Genotype. 
In the two subjects whose CTL clones did not recognize 
the dominant autologous HIV-1 genotype (K588Q), CTL 
precursor analysis was performed to assess the degree of the 
CTL  response  against  gp41/584-592  (588K)  and  variant 
(K588Q) peptide. For each subject, two parallel CTL pre- 
cursor  assays were  performed.  One  assay  was  stimulated 
with fresh autologous PBMC incubated with the 588K and 
p17/77-85 peptides and the other was stimulated with fresh 
autologous PBMC incubated with K588Q and p17/77-85 
peptides, p17/77-85 is an HLA-A2-restricted CTL epitope 
recognized by CTL from each subject, and served as a pos- 
itive control in  each  assay. The parallel assays from each 
subject were tested on the same day against  the same CTL 
targets,  either  autologous B-LCL  alone  or B-LCL incu- 
bated with p17/77-85, 588K, or K588Q at 1 p,g/n'ft.  Split- 
well  analysis  was  used  to  determine  whether  there  were 
two populations of CTL responsible for lysis of these tar- 
gets.  For subject 010-115i, the precursor frequency against 
p17/77-85  was  similar  in  each  assay (185  vs.  155/106 
PBMC; Fig.  5). As expected, PBMC stimulated with 588K 
show  a  higher  degree  of recognition of the  index 588K 
peptide  than  of K588Q  (620 vs.  224/106  PBMC).  Like- 
wise,  PBMC  specifically stimulated with the variant pep- 
tide  (K588Q)  show  a  higher precursor frequency against 
the variant than against  588K (141 vs.  14), yet this is lower 
than the precursor frequency than can be generated against 
the index 588K peptide. A similar result was obtained for 
subject 18030. The precursor frequency against  the control 
p17  peptide  was  similar  in  both  cases  (163  vs.  177/106 
PBMC) yet the maximum frequency against the 588K pep- 
tide was 291/106 and against the K588Q peptide it was 48/ 
106. In each case there is a four to six-fold higher precursor 
frequency against  the  subdominant in vivo HIV-1  geno- 
type. 
The  existence of CTL able  to preferentially recognize 
the  variant peptide was  confirmed by cloning.  Split-well 
analysis made it possible to select wells from the precursor 
assay plates with especially high activity directed against  the 
variant peptide. Cells from these wells were cloned at lim- 
iting dilution in the presence of PHA, irradiated allogeneic 
feeder cells, and rlL-2. Three CTL clones isolated from sub- 
ject 18030 were preferentially able to recognize the K588Q 
epitope. A peptide titration from one of these CTL clones 
is shown in Fig.  6.  This experiment demonstrates that the 
50% maximal lysis  of the  K588Q  variant by CTL  clone 
18030 J18 is the same as that of the 588K epitope by CTL 
clone  18030  B31.  It  also  demonstrates  that  there  is  no 
cross-reactivity of the  CTL  clones  for the  two  peptides. 
The TCP, of this CTL clone is distinct from the previously 
isolated CTL that recognize the 588K peptide and utilizes 
the V(x7, Jc115.3, V136, and J81.5 gene segments, providing 
further evidence of the marked heterogeneity in TCI< able 
to recognize the B14-restricted gp41  epitope (Fig. 7). 
Discussion 
In this study we demonstrate that CTL with heteroge- 
neous TCI< are able to recognize an epitope in gp41 that is 
restricted by the HLA-B14 molecule, and that this epitope 
Ve7  N 
C  A  V  R  A  P  T 
TGT GCT  GTG AGG GCC CCA ACA 
Vp6  N-D~-N 
S  S  P  R  T  G  T  G 
AGC AGC  CCT CGG ACA GGT ACG GGC 
Figure 7. 
Je 15.3  #/total # 
S  G  G  S  Y  I  P  T  F  G  R  G  T  S  L 
TCA GGA GGA AGC TAC ATA CCT ACA TTT GGA AGA GGA ACC AGC CTT  9/9 
Jp 1.5 
N  Q  P  Q  H  F  G  D  G  T  R  L  S  I  L 
AAT CAG CCC CAG CAT TTT GGT GAT GGG ACT CGA CTC TCC ATC CTA 
TCP,.-(x and -[3 sequences of CTL clone 18030J18 (EMBL/Genbank/DDBJ accession numbers U51446 and U51447). 
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12/12 is frequently reco~rized by HIV-l-infected subjects with this 
haplotype. We also show that the dominant in vivo quasi- 
species can vary markedly among persons of the same HLA 
haplotype. In two of the individuals studied in this report 
the  dominant  CTL  response is  directed  against  a  HIV-1 
variant  that  makes  up  the  minority  of the  in  vivo  se- 
quences.  The ability of one of these subjects to recognize 
the major in vivo variant was confirmed by isolation of a 
CTL clone that preferentially recognized the dominant in 
vivo HIV-1 variant. However, despite the presence of CTL 
responses to the  major in vivo variant, this  response does 
not become dominant. 
Few studies have evaluated the TCR usage of CTL clones 
directed against the same viral epitope in different individ- 
uals,  and  none  has  correlated  this  with  the  in  vivo  viral 
quasispecies. Most of the prior work on TCR usage of vi- 
rus-specific, class I-restricted CTL has concentrated on the 
CTL response to influenza A, an acute viral infection. Two 
studies have focused on the CTL response to the HLA-A2- 
restricted matrix epitope  (58-66)  of influenza A,  the  only 
HLA-A2-restricted  epitope  described  in  this  virus  (4,  5). 
Lehner  et.  al.  (5)  determined  that ~85%  of CTL  clones 
specific for this epitope utilize V[317.  A study of CTL spe- 
cific  for  a  HLA  B27-restricted  influenza  nucleoprotein 
epitope  (383-391)  found  that  five of eight  of these  CTL 
clones utilized the VI37 gene (6). 
The only studies that have addressed CTL TCR usage in 
chronic viral infections have focused on HIV-1  and EBV 
infections. In a recent study (8) an extremely restricted pat- 
tern of TCR  usage has been described against a HLA B8- 
restricted EBV epitope. Six CTL clones from five subjects 
were isolated and subjected to TCR analysis. Identical TCR 
protein  sequences  were  used  by CTL  from each  of four 
healthy unrelated subjects and a clone from a fifth subject 
differed by only two amino acids. It has been proposed that 
the extremely restricted TCR usage against the EBV epitope 
may be the consequence of its being a chronic viral infec- 
tion that has evolved with its host over the history of hu- 
man existence,  and as a consequence,  the narrowed TCR 
gene usage may be an adaptation of the host to this virus (8). 
In  this  study,  common  TCR  elements  were  found  in 
five of nine of the CTL clones  (lines)  specific for the B14 
peptide epitope in HIV-1 gp41. However, other heteroge- 
neous  TCtL from two other individuals  were still  able to 
recognize this CTL epitope to the same degree. The isola- 
tion ofa CTL clone (18030 D6) with TCR-o~ and -13 se- 
quences identical to those of a CTL clone isolated from the 
same subject 11  mo earlier provide another example of the 
persistence  of these  CTL  in  the  circulation  (7,  9).  This 
finding also demonstrates that caution must be used before 
one assumes that a dominant TCR usage in a peptide-stim- 
ulated  line  allows one to attribute  the  TCR  usage to the 
CTL  clone  responsible  for  the  epitope  specificity.  The 
TCR. sequences of CTL line 18030 G14 were derived after 
two  rounds  of in  vitro  peptide  stimulation,  and  this  line 
maintained excellent recognition of peptide-sensitized tar- 
get cells  at low E/T ratios, yet the TCR sequences of the 
epitope-specific CTL clone were in the minority (Fig. 2). 
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In two of the subjects described in this paper, the major- 
ity of in vivo HIV-1 sequences are not recognized by clones 
isolated from each of these patients. The sequences in this 
report were  derived  from proviral DNA.  Since  these  se- 
quences remained stable over 8  (subject 18030)  and 32 mo 
(subject  010-115i),  they  are  likely  to  also  reflect  plasma 
RNA  sequences  (24).  A  precursor  frequency  analysis  in 
each case demonstrated a lower frequency of CTL specific 
for this  dominant  HIV-1  sequence  and  split-well  analysis 
revealed the presence of a distinct CTL population in each 
case that was able to recognize the variant peptide. The iso- 
lation ofa CTL clone from subject 18030  (118) that recog- 
nizes the dominant in vivo sequence variant and that has a 
completely unique  TCR  implies  that  the  relative lack of 
CTL precursors directed against this variant is not due to a 
"hole" in the TCR. repertoire and also confirms the ability 
of this  peptide  to  bind  to  the  HLA-B14 molecule.  This 
would speak against lack of HLA binding as a reason for the 
lower level of CTL precursors.  This  CTL clone  can lyse 
target cells at the same peptide concentrations as CTL clones 
that recognize the gp41/584-592  peptide, thus the reasons 
for  the  diminished  precursor  frequency  are  unclear.  We 
cannot rule out the possibility that the amino acid substitu- 
tion  within  this  epitope,  or  a  substitution  in  one  of the 
flanking regions of this HIV-1 variant, has an adverse effect 
on antigen presentation (25-27) resulting in the lower pre- 
cursor frequency. Other investigators (28,  29) have shown 
that a dominant immunization with an alloantigen was able 
to inhibit CTL responses to a second alloantigen; a similar 
mechanism could potentially prevent effective CTL-medi- 
ated immunity to HIV-1 variants that arise over the course of 
infection. If a deficiency in antigen presentation is responsi- 
ble  for  an  ineffective  CTL  response  against  a  dominant 
variant, efforts to augment existing CTL responses through 
a peptide-based immunotherapeutic agent designed to in- 
crease CTL activity against HIV-1 variants might bypass this 
mechanism of immune escape. 
We also investigated the potential role of TCR antago- 
nism in  the  two individuals  with  nonrecognized  variants. 
Although there was evidence of antagonism by the K588Q 
peptide, this effect was only evident at relatively high pep- 
tide  concentrations  (>10  ~zg, data  not  shown)  and  is  in 
contrast to recent reports (30,  31)  showing potent antago- 
nistic  effects of peptides at extremely low concentrations. 
The significance of CTL antagonism in vivo remains un- 
clear. 
Because  of the  small number of subjects  evaluated,  we 
cannot correlate TCR  usage or patterns of fine specificity 
with disease progression, but it is interesting that such a di- 
verse repertoire of TCP. is able to recognize this epitope. 
To  our  knowledge  this  type  of study,  assessing  the  fine 
specificity of CTL clones by titrating peptides representing 
both  natural  sequence  variation  and  alanine  substitutions, 
and attempting to correlate this fine specificity with the rel- 
evant TCR  sequences has not been performed for a class 
I-restricted CTL epitope.  A  similar study  (32)  describing 
CD4-restricted myelin basic protein-specific CTL has been 
published, however no titrations were performed and rela- tively high peptide  concentrations were used.  These  types 
of studies  may prove more  useful for evaluating CTL re- 
stricted by HLA molecules for which the crystal structure is 
known, thereby helping to determine the ternary structure 
of the  TCR-peptide-HLA  complex.  The  significance  of 
1-  or  2-1og differences  in  the  recognition  of a  particular 
HIV-1  variant by a  particular  clone  is  also  uncertain.  Al- 
though it is reasonable to assume that higher affinity TCR 
would be more effective at suppressing viral replication in 
vivo, this remains unproven and experiments on the recog- 
nition of acutely infected cells by HIV-1 variants contain- 
ing point mutations representing natural sequence variation 
are needed. 
The findings that subjects with a shared HLA allele  can 
frequently recognize the same HIV-1 epitope and that CTL 
with differing fine specificities and heterogeneous TCR us- 
age can result from natural infection have important impli- 
cations for vaccine development. If  subjects with more com- 
mon HLA alleles  target similar  HIV-1  epitopes  one  could 
hypothesize that a peptide-based vaccine designed to elicit 
CTL  responses  against  these  HIV-1  epitopes  and  their 
common variants could benefit a large segment of the pop- 
ulation.  It is  conjectural  at  this  time  whether  HIV-l-anti- 
genic variation within CTL epitopes plays a role in HIV-1 
disease progression. A  model of HIV-l-antigenic variation 
suggests  that  a  narrowly  directed  CTL  response  directed 
against a conserved epitope may be more effective at con- 
taining  HIV-1  replication  than  a  diverse  response  against 
multiple  epitopes  (33).  A  central postulate  of this model is 
that CTL-mediated suppression of a HIVq  variant can lead 
to outgrowth of a nonrecognized HIV-1 mutant. The mu- 
tant then predominates until a new CTL response is gener- 
ated;  meanwhile  the  original  CTL  response  wanes.  Pre- 
sumably, these shifting CTL responses are the cause of the 
HIV-l-antigenic  oscillations  observed  in  one  of the  two 
subjects in that report. We have shown in two of our sub- 
jects  that  a  dominant  CTL  response  can  persist  against  a 
variant that makes up a minority of in vivo sequences, and 
in these cases  no antigenic oscillation is seen over the time 
period studied. If this sustained CTL response is responsible 
for the continued suppression of the minority HIV-1 vari- 
ant,  one  could  hypothesize  that  enhancing  the  CTL  re- 
sponse against the dominant variant would further suppress 
HIV-1  replication.  Furthermore,  having  a  diverse  reper- 
toire of CTL able to recognize naturally occurring variants 
in place before infection, or very soon after infection is es- 
tablished,  would possibly be more effective than the situa- 
tion in natural infection where mutations may occur within 
CTL epitopes after substantial  damage to the imnmne sys- 
tem has taken place.  In cases where virus variants generate 
less vigorous CTL responses, immunotherapeutic  regimens 
designed to augment these responses may prove beneficial. 
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